Axsome Therapeutics (AXSM) said Tuesday that the phase 3 trial of solriamfetol as a potential treatment for attention deficit hyperactivity disorder achieved its primary and key secondary endpoints, demonstrating "statistically significant" improvement in symptoms and disease severity.

The study met its primary endpoint of a statistically significant reduction in the Adult ADHD Investigator Symptom Rating Scale compared with placebo at week six. The study also achieved the key secondary endpoint of a significant reduction in overall ADHD disease severity, Axsome added.

Solriamfetol was also well-tolerated in the study, with no serious adverse events reported, according to Axsome.

Axsome Chief Executive Officer Herriot Tabuteau said the company plans to start a solriamfetol trial in pediatric patients this year.